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Racial Differences in the Incidence of Steroid Diabetes in 
Renal Transplant Patients 
Francis Dumler, MD,* Hajime Hayashi, PhD,** Jay Hunter, BS,** and Nathan W. Levin, MD^ 
We have studied the development of steroid-induced di-
abetes in a population of 143 renal allograft recipients who 
were nondiabetic before transplantation. Steroid-induced 
diabetes developed In 9.8% of patients. However, in 
blacks its incidence was significantly higher than in whites 
(17.3% vs 5.5% respectively; p < .01). The development of 
steroid-induced diabetes was not associated with a higher 
frequency of HLA-B8 or HLA-Bwl5 in either race. In black 
graft recipients, HLA-BI4 was significantly more frequent (p 
< .001) among those who developed steroid-induced di-
abetes than in insulin-dependent diabetic (Type I) and 
nondiabetic recipients. The clinical course of patients with 
steroid-induced diabetes has been similar to that of nonin-
sulin-dependent diabetics (Type II). 
T h e occurrence of diabetes mellitus in renal allograft 
recipients who are not diabetic before transplantation has 
been well documented, the incidence varying from 6 to 
25% (1-6). A greater freq uency of HLA-B8 and Bw15 has 
been reported in renal transplant recipients with significant 
glucose intolerance which suggests the uncovering of a 
latent diabetic state by corticosteroid therapy (7). We have 
studied the development of steroid-induced diabetes in a 
racially mixed population of renal allograft recipients and 
have found a higher incidence of steroid diabetes in blacks 
than in whites. 
Patients and Methods 
The population studied consisted of 171 patients who were 
transplanted at Henry Ford Hospital during the past seven 
years. Of these, 129 were nondiabetic, 28 were juvenile-
onset, insulin-dependent diabetics (Type I diabetes) diag-
nosed before transplantation, and 14 developed diabetes 
after receiving a renal allograft and while they were on 
maintenance corticosteroid therapy (Table I). 
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The diagnosis of steroid diabetes was made on the basis of 
a negative history for diabetes before transplantation, a 
normal fasting blood glucose up to the time of receiving 
renal allograft, and the presence of persistent fasting hyper-
glycemia in the post-transplant period while on chronic 
maintenance corticosteroid therapy. HLA typing was car-
ried out on all patients as previously described (8). Fisher's 
exact probability test was used for statistical analysis (9). 
Results 
Of 143 patients who did not have diabetes before trans-
plantation, 14 (9.8%) developed steroid diabetes at varying 
times after surgery. Analysis by race of the population at 
risk indicated that 9 of 52 blacks (17.3%) developed steroid 
diabetes as compared to 5 of 91 (5.5%) whites, a highly 
significant difference (p < .01). 
The frequency of the HLA antigens B8 and Bwl5 in our 
patient population is shown in Table II. None of the white 
patients with steroid diabetes was positive for B8 or Bwl5, 
and the frequency of Bw15 did not differ between blacks 
with steroid diabetes and nondiabetic blacks. Among 
blacks with steroid diabetes, the frequency of HLA B14 was 
significantly higher (p < .001) than for insulin-dependent 
diabetics (Type I) or nondiabetics (Table II). No differences 
were noted in the frequency of HLA-B7, B12, or BIB among 
black or white nondiabetic, insulin-dependent, or steroid-
induced diabetic patients. 
In our patients wfth steroid-induced diabetes, the mean age 
was 42 ± 12 years, and the mean duration of onset after 
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TABLE I 
Steroid-Induced Diabetes in Renal Transplant Recipients: 
Racial Distribution 
Patient Groups 
Number of Patients 
Blacks Whites Total 
Nondiabetics 
Insulin-dependent 
Steroid-induced 
Diabetics 
43 
13 
9 
65 
86 
15 
106 
129 
28 
14 
171 
transplantation was 9 ± 5 months. A positive family history 
of diabetes mellitus was present in two of the 14 patients 
who developed steroid diabetes. Only one of the patients 
with steroid-induced diabetes was obese. There were no 
differences in mean body weights between blacks and 
whites or between patients with steroid-induced diabetes 
and nondiabetic recipients. The frequency of furosemide 
usage and its dosage were similar in blacks and whites and 
in patients with and without steroid-induced diabetes. All 
black patients have required insulin for control of blood 
glucose. Two of the five white patients were managed by 
diet alone and have a normal glucose tolerance at a lower 
steroid dose. No patient has developed ketoacidosis, and 
three patients who lost their grafts are no longer diabetic 
after corticosteroids were discontinued. 
Discussion 
The 9.8% incidence of steroid-induced diabetes in our 
series agrees with that cited in previous reports (1-6). A 
greater frequency of steroid diabetes in blacks has been 
reported by David, et al (6), who found a higher frequency 
of HLA-A28 in blacks and attributed the greater incidence 
of steroid diabetes in blacks to this fact. In our series, even 
when we excluded patients who were HLA-A28 positive, 
the incidence of steroid diabetes in blacks (15%) was still 
higherthan in whites (6%). ft has recently been shown that 
HLA-A2 may be a marker for insulin-independent or in-
sulin-requiring diabetes (Type II) in South African blacks 
(10). We thus evaluated the frequency of this particular 
phenotype among our patients but found no differences 
between nondiabetics and steroid diabetics. 
We could not document a higher frequency of HLA-B8 or 
Bw15 in steroid diabetics, black or white, as has been 
reported previously (7). Others have also failed to reveal 
such an association (5). None of our black, insulin-depen-
dent diabetic patients (Type I) was positive for B8 or Bw15. 
This finding agrees with reports that indicated no associa-
tion between the HLA-B locus and Type I diabetes in black 
Americans (11,12). However, we did find in blacks an 
TABLE II 
Frequency (%) of HLA A2, A28, B8, B14 and Bw15 Antigens 
in Renal Transplant Recipients 
Insulin-
HLA Ant igen Nondiabet ics 
dependent 
Diabetics 
s tero id 
Diabetics 
Whites (N=86) (N = 15) (N=5) 
A2 46 63 80 
A28 8 5 0 
38 27 37 0 
B14 10 0 20 
Bw15 14 32 0 
Blacks (N=43) (N = 13) (N=9) 
A2 33 46 44 
A28 19 31 33 
B8 9 0 0 
B14 2 0 33* 
Bw15 2 0 10 
* p<.001 when compared to nondiabetics and insulin-dependent diabetics (Type I) 
association between the development of steroid diabetes 
and an increased frequency of HLA-B14. 
The mechanisms for the development of steroid diabetes 
are not clear. Several effects of corticosteroids may be 
relevant, such as an increase in gluconeogenesis, impaired 
peripheral utilization of glucose, insulin resistance, and 
induction of hyperglucagonemia. It has been recently 
shown that steroid therapy, even in renal transplant recip-
ients with a normal glucose tolerance test, results in a 
significantly enhanced insulin release and an increased 
numberof insulin receptors in monocytes (13). In general, 
patients with steroid diabetes are older, are cadaver al-
lograft recipients, have been treated several times for acute 
rejection episodes, and acquire their diabetes during the 
first three months after transplantation. A family history of 
diabetes mellitus is present in one third to one halfof these 
patients, and hyperglycemia is usually controlled without 
insulin (1-6). 
We could not find any differences in the type of transplant 
(cadaveric or living related), family history of diabetes, total 
dose of steroids, and mode of steroid administration (daily 
versus alternate day) between patients who developed 
steroid diabetes and those who did not. Others have also 
found no consistent effect of alternate day steroid therapy 
on the development of steroid- induced diabetes (14). 
Whether the lower dosages of steroids currently used in 
renal transplantation wil l lead to a decreased incidence of 
steroid diabetes remains to be determined. The mean fol-
low-up of these patients is 33 ± 25 months, and complica-
tions attributable to steroid diabetes have yet to occur. In 
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this series, steroid-induced diabetic patients did not have 
an increase in mortality (10 per 1,000 patient months) when 
compared to insulin-dependent diabetics (16 per 1,000 
patient months) or to nondiabetic renal transplant recip-
ients (18 per 1,000 patient months). 
We hypothesize that steroid-induced diabetes as seen in 
the renal transplant population is distinct from insulin-
dependent diabetes (Type I) and that clinically it resembles 
maturity-onset, noninsulin-dependent (Type II) diabetes 
(15). Why blacks are more prone to developing steroid 
diabetes is not clear from this study. The population ana-
lyzed is a selected one, since all patients have developed 
end-stage kidney disease. Analysis of data from the Michi-
gan Kidney Registry for Southeastern Michigan indicates 
that diabetes mellitus is more frequently associated with 
end-stage kidney failure in blacks than in whites. The data 
also suggest that in the black diabetic population renal 
failure is more commonly associated with noninsulin de-
pendent (Type II) diabetes (Weiler JW, personal commu-
nication). Many socioeconomic and genetic factors may 
not only make diabetes more severe in black patients, i.e., 
development of end-stage kidney disease, but may also 
predispose them to developing diabetes under certain 
stressful condi t ions, i.e., maintenance cort icosteroid 
therapy. 
In summary, these data allow the clinician involved in renal 
transplantation to identify a group of patients at particular 
risk for steroid-induced diabetes, the black renal transplant 
recipient. They also suggest that once diabetes occurs, its 
clinical course wil l be similar to that of Type II diabetes 
mellitus and that remission may occur if steroid therapy is 
withdrawn. 
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